Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
前日終値
$0.2297
−$0.0117 · -4.85%
日中の時刻はETです。市場データは遅延する場合があります。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日中レンジ
現在 $0.2297
52週レンジ
現在 $0.2297
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
70
割安
センチメント
46
まちまち
リスク
75
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日中レンジ
現在 $0.2297
52週レンジ
現在 $0.2297
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 4.02億 USD | 4.59億 USD | 4.47億 USD | 4.48億 USD | 4.3億 USD |
| 売上原価 | 2.9億 USD | 3.12億 USD | 3.04億 USD | 2.94億 USD | 2.7億 USD |
| 粗利益 | 1.11億 USD | 1.47億 USD | 1.43億 USD | 1.54億 USD | 1.6億 USD |
| 研究開発 | 3775.3万 USD | 4794.2万 USD | 4973.2万 USD | 5712.9万 USD | 5775.2万 USD |
| 販売・一般管理 | 8397.1万 USD | 9118.6万 USD | 9268.5万 USD | 9444.9万 USD | 9405.5万 USD |
| 営業費用 | 1.38億 USD | 1.39億 USD | 1.42億 USD | 1.52億 USD | 1.52億 USD |
| 受取利息 | — | 119.2万 USD | — | — | — |
| 支払利息 | 3531万 USD | 1295.4万 USD | 1162.4万 USD | 1063.2万 USD | 812.9万 USD |
| 減価償却費と償却費 | 794.2万 USD | 615万 USD | 590.5万 USD | 452.7万 USD | 551.3万 USD |
| 営業利益 | −2644.2万 USD | 783.9万 USD | 50.4万 USD | 238.2万 USD | 814.8万 USD |
| 純利益 | −4919.4万 USD | −159.1万 USD | −1554.5万 USD | −928万 USD | −534.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.00
上昇余地(770.70%)この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI82.12万0.00%2.3兆 USD0.03%$381.94+0.63%
Fidelity Enhanced Small Cap ETFFESM34.61万0.01%64.1億 USD0.28%$45.46+0.46%
Vanguard Extended Market ETFVXF31.3万0.00%954億 USD0.05%$235+0.80%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM2.84万0.00%6.94億 USD0.89%$57.70+0.92%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.65万0.00%26.7億 USD0.36%$53.16+0.64%
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM
Invesco RAFI US 1500 Small-Mid ETFPRFZAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。